Welcome to our dedicated page for Ashland SEC filings (Ticker: ASH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ashland Inc. files regular SEC disclosures that reveal how the company's specialty chemicals business performs across distinct market segments. For specialty chemical manufacturers, segment-level financial breakdowns matter significantly because pharmaceutical ingredients, personal care formulations, and industrial additives operate under different margin structures and market dynamics. The company's 10-K annual reports detail these segment economics, showing which business lines drive profitability and where operational challenges exist.
Investors analyzing Ashland's filings typically focus on several disclosure areas unique to specialty chemicals. Revenue breakdowns by end market reveal exposure to pharmaceutical, personal care, coatings, and construction industries. Geographic revenue splits indicate regional demand patterns and currency exposure. Raw material sourcing discussions highlight supply chain dependencies, particularly important for specialty chemical feedstocks with limited supplier bases. Manufacturing footprint descriptions show facility locations and capacity utilization trends affecting operational efficiency.
Our platform provides AI-powered analysis of Ashland's quarterly 10-Q reports, annual 10-K filings, and proxy statements. When executives file Form 4 insider transaction reports, these appear immediately, letting you track whether leadership buys or sells shares. Material events disclosed through 8-K filings surface operational changes, strategic announcements, and corporate developments between scheduled earnings releases. For a diversified specialty chemicals company like Ashland, these interim disclosures often contain significant operational updates affecting specific business segments.
SEC filings for chemical manufacturers include technical disclosures about environmental compliance, operational safety, and regulatory matters that casual investors might overlook but that carry material financial implications. Our AI summaries highlight these elements, explaining what complex accounting treatments or footnote disclosures mean for segment profitability and cash generation. Access quarterly earnings details without reading 50-page financial statements, and track executive compensation structures through annual proxy filings to understand management incentives.
Ashland Inc. director reports routine deferred stock unit grant. On 12/31/2025, an Ashland Inc. (ASH) director acquired 426 Common Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors at a price of $58.67 per unit. Each Common Stock Unit is equivalent to one share of Ashland common stock and is payable in common shares when the director separates from service as a director, subject to any deferral elections under the plan. Following this transaction, the director beneficially owns 4,818 Common Stock Units, a balance that also reflects additional units previously acquired in lieu of cash dividends.
Ashland Inc. director Sanat Chattopadhyay reported acquiring additional deferred equity tied to the company’s stock. On 12/31/2025, he received 245 Common Stock Units at $58.67 per unit under Ashland’s Deferred Compensation Plan for Non-Employee Directors, which is exempt under Rule 16b-3. Each unit is equivalent to one share of Ashland common stock and is payable in common stock when he separates from board service, subject to any deferral election. Following this award, he beneficially owns 1,679 Common Stock Units, a figure that includes units accumulated in lieu of cash dividends.
Ashland Inc. is asking stockholders to review its 2026 proxy and vote at a virtual annual meeting on January 20, 2026. Stockholders will elect eight directors, ratify Ernst & Young LLP as auditor for fiscal 2026, and cast a non-binding advisory vote on executive compensation.
The company, a global additives and specialty ingredients supplier, reports fiscal 2025 sales of $1.824 billion, down after strategic portfolio optimization and the sale of the Avoca business. Fiscal 2025 includes an operating loss of $775 million, driven largely by a $706 million goodwill impairment and a $175 million loss on the Avoca sale. Non-GAAP adjusted EBITDA was $401 million with a 22.0% margin, and adjusted EPS (excluding intangible amortization) was $3.38.
The Board highlights $30 million of restructuring savings, a $60 million manufacturing optimization program, and ongoing globalization and innovation investments. Governance practices include a majority-independent Board, a combined Chair/CEO role balanced by a Lead Independent Director, four fully independent committees, strong attendance, stock ownership guidelines, a clawback policy, and anti-hedging rules. Executive and director pay is positioned as pay-for-performance, with significant equity-based and incentive-linked components tied to metrics such as adjusted EBITDA, innovation revenue, RONA, adjusted EPS and relative total shareholder return.
Standard Investments LLC and affiliates have filed a Schedule 13D on Ashland Inc. after building a sizable position. The group reports beneficial ownership of 2,625,000 shares of Ashland common stock, representing 5.7% of the outstanding shares, based on 45,718,113 shares outstanding as of October 31, 2025. The shares were acquired by Standard Latitude Master Fund for a total purchase price of $133,023,241, funded with working capital through open-market purchases.
In addition, Standard Latitude Master has cash-settled total return swaps referencing 1,900,000 Ashland shares, equal to 4.2% of the outstanding stock, giving the group combined economic exposure to approximately 9.9% of Ashland. The investors state they view Ashland as an attractive opportunity and may engage with management, the board and other stakeholders on topics such as strategy, capital allocation, governance and potential strategic alternatives, and may increase or reduce their position over time.
Ashland Inc. (ASH) reported an equity compensation grant to a senior executive. On 11/19/2025, the company granted its SVP and GM, Life Sciences, 6,136 Restricted Stock Units (RSUs), each representing one share of Ashland common stock. These RSUs vest in three equal installments starting one year from the grant date, as long as the executive remains continuously employed.
On the same date, the executive also received 13,807 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share. These SARs become exercisable ratably over three years beginning on the first anniversary of the grant and expire on 11/19/2035. The filing reflects ongoing use of Ashland’s shareholder‑approved incentive compensation plans.
Ashland Inc. (ASH) reported an equity compensation grant to a senior executive. On November 19, 2025, the company awarded 3,965 Restricted Stock Units (RSUs), each representing one share of Ashland common stock, and 8,922 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share.
The RSUs vest in three equal installments beginning one year from the grant date, as long as the executive remains continuously employed with Ashland. The SARs were granted under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan and become exercisable ratably over three years, starting on the first anniversary of the grant date.
Ashland Inc. (ASH) reported an equity award to its Chair and CEO, Guillermo Novo. On 11/19/2025, he received 43,495 Restricted Stock Units (RSUs), each representing one share of Ashland common stock, granted under the company’s shareholder‑approved incentive plan and exempt under Rule 16b-3.
The RSUs vest in three equal installments beginning one year from the grant date, as long as he remains continuously employed. Novo was also granted 97,864 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share, expiring on 11/19/2035. These SARs become exercisable ratably over three years starting on the first anniversary of the grant date, and both awards are held directly.
Ashland Inc. (ASH) reported an equity award grant to its senior finance executive. William Whitaker, the company’s SVP, CFO and PFO, received 10,280 restricted stock units (RSUs) on November 19, 2025 under Ashland’s shareholder-approved incentive plan. Each RSU represents one share of Ashland common stock and vests in three equal installments starting one year from the grant date, as long as he remains continuously employed.
Whitaker was also granted 23,131 stock appreciation rights (SARs) on the same date at an exercise price of $50.58 per share, expiring on November 19, 2035. These SARs become exercisable ratably over three years beginning on the first anniversary of the grant date.
Ashland Inc. (ASH) filed a Form 4 reporting new equity awards to its SVP and CTO, Osama M. Musa. On November 19, 2025, he received 6,379 Restricted Stock Units (RSUs), each representing one share of Ashland common stock. These RSUs vest in three equal installments starting one year after the grant date, as long as he remains continuously employed by the company.
He was also granted 14,354 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan. The SARs become exercisable ratably over three years, beginning on the first anniversary of the grant date, and expire on November 19, 2035. These awards are part of Ashland’s shareholder-approved incentive plans.
Ashland Inc. (ASH) reported an equity award for senior vice president and general manager of Personal Care, James P. Minicucci. On 11/19/2025, he received 5,049 Restricted Stock Units (RSUs), each representing one share of Ashland common stock, granted under the company’s shareholder-approved incentive plan. These RSUs vest in three equal installments starting one year from the grant date, contingent on continued employment.
On the same date, he was also granted 11,361 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan. The SARs become exercisable ratably over three years beginning on the first anniversary of the grant and expire on 11/19/2035.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
